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SECTION 1 Basic principles
Principles of clinical epidemiology
Annette C. Moll, Michiel R. de Boer and Lex M. Bouter
INTRODUCTION
During the last decade evidence-based medicine (EBM) became a
dominant approach in many medical fields, including ophthalmol-
ogy.''' Clinical epidemiologic studies provide evidence that can aid the
decision-making process. The aim of this chapter is to provide the
reader with some basic knowledge to allow them to judge the value
of clinical epidemiological papers. Examples from ocular oncology will
be used to illustrate the methodological principles.
RESEARCH QUESTION
A clinical epidemiological study should always start with a well-
defined research question. Similarly, when reading a paper, one should
always keep in mind the question(s) the authors wish to address (Fig.
1.1). Research questions can be aimed at explanation or description
and are often categorized as etiologic, diagnostic or prognostic (Table
1.1). For example, an explanatory research question related to etiology
in the field of ocular oncology is: are children born after in vitro fer-
tilization at higher risk of developing retinoblastoma than children
born after natural conception?' A correct explanatory research question
should contain information on the patients, interventions, contrast and
outcomes (PICO).
OUTCOME MEASURES
Traditionally, prevalence, incidence and mortality (survival) have been
the outcome measures in clinical cancer epidemiology studies. More
recently, quality of life has become increasingly popular. In ophthal-
mic oncology, visual acuity is an important outcome measure.
Prevalence refers to the proportion of the population with the
condition of interest. Usually prevalence is given for a specific moment
in time (point prevalence), but sometimes it is estimated for a period
of time (e.g. 1-year or lifetime prevalences). For example, the lifetime
prevalence of uveal melanoma in a white population with oculo
(dermal)melanocytosis is estimated to be 0.26%.4
I ncidence Whereas prevalence relates to existing cases, incidence
relates to the proportion of new cases in a certain population. It is
i
mportant that the population under investigation is at risk of develop-
ing the condition. For example, persons with bilateral enucleation are
no longer at risk of developing uveal melanoma. There are two different
m
easures of incidence: cumulative incidence (CI) and incidence
density (ID). CI is the proportion of new cases in a population at risk
over a specified period. For example, the cumulative incidence of
second malignant neoplasms in hereditary retinoblastoma patients is
17% at the age of 35 years.' ID refers to the rate of developing the
condition during follow-up, usually expressed as a proportion of
person-years at risk.
Mortality refers to the incidence of death. The mortality rate can be
all-cause, indicating all deaths, or disease specific, for instance mortal-
ity caused by melanoma or retinoblastoma. Case fatality rate refers to
the proportion of patients with a given disease who will die from that
disease, and thus reflects the seriousness of the condition. More for-
mally put, it concerns the cumulative incidence of death among the
diseased. Often the survival rate is presented. For example, the 2-year
survival rate after breast cancer metastases to the choroid is 30%. 6 This
means that of all the patients diagnosed with choroidal metastases
from breast cancer, 30% are still alive 2 years after diagnosis. It is
important to realize that these mortality figures are highly dependent
on certain characteristics of the population, such as age, stage of
cancer, and comorbidity.
Quality of life With the increasing survival rate and severe side
effects of some treatment modalities, quality-of-life measures have
become increasingly important in ophthalmic oncology. These mea-
sures encompass symptoms as well as physical, social and psychologi-
cal functioning from the patient's perspective. Usually quality of life
is assessed with a structured questionnaire and scores are summarized
assuming an interval scale. Several questionnaires have recently been
developed for patients with ocular diseases, such as the measure of
outcome in ocular disease (MOOD)!
MEASURES OF ASSOCIATION
In epidemiological research we are usually interested in associations
between certain interventions or exposures and their respective out-
comes, e.g. is there an association between paternal age and retino-
blastoma in the offspring?' There are several statistical approaches that
can be used to quantify associations, either as a ratio or as a difference,
depending on the study design and statistical method used (Table
1.2).
Relative risk The ratio of cumulative incidence between a group of
exposed and unexposed individuals or treated and untreated patients
is the relative risk (RR). For example, in The Netherlands the RR of
retinoblastoma in children conceived by in vitro fertilization is between
4.9 and 7.2. This implies that the risk of developing retinoblastoma is
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Fig. 1.1 Steps in designing clinical epidemiological research.
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between 4.9 and 7.2 times higher for children conceived after IVF
than for naturally conceived children.
Hazard ratio The ratio of incidence density between a group of
unexposed and exposed patients is the hazard ratio (HR), which has
a similar interpretation to the RR. This measure is often used in rela-
tion to mortality, because we are generally interested not only in the
proportion of patients that die, but also in the time from baseline
(diagnosis or start treatment) until death. A special application of the
HR is the ratio of the observed to the expected number of cases (0/E
ratio). In this case the observed ID is calculated for the study popula-
tion and this is compared to the expected ID derived from a population
registry (e.g. cancer registration). For example, in a study of lifetime
risks of common cancers among hereditary retinoblastoma survivors
(n = 144), 41 cancer deaths were observed, whereas only 7.58 deaths
due to cancer were expected. These data can be expressed as a
standardized mortality ratio of 5.41.9
Odds ratio The odds ratio (OR) is the most commonly reported
measure of association in the literature, because this is the statistic that
can be derived from popular logistic regression analysis. The OR is the
ratio of the odds of outcome of interest between the exposed and the
unexposed.
Differences in risk are preferably reported as the outcome of ran-
domized controlled trials. The risk difference (RD) is easy to interpret
and can be used to calculate the number of patients needed to treat
(NNT) to prevent one extra event (e.g. death) compared to the stan-
dard treatment or placebo. The NNT can be calculated as inverse of
RD (1/RD).
Differences in mean score For scores on interval scales, such as
quality of life, differences in mean score between exposed and
unexposed participants are the only measure of interest.
STUDY DESIGNS 1
Table 1.2	 The relation between outcome, measures of association, study design, and statistical methods
Outcome Measure of association Computation Study design Statistical method
Prevalence Prevalence rate P1/P2 Cross-sectional x2 test
Logistic regression
analysis
Prevalence difference P 1 - P2 Cross-sectional x2 test
Odds of exposure Odds ratio Odds of exposure group Case control study (cohort x2 test
1/odds of exposure
group 2
study, RCT) Logistic regression
Cumulative Relative risk Ch/Cl2 Cohort study/RCT x2 test
incidence (CI) Risk difference CI, — Cl2 RCT
Incidence density (ID) Hazard ratio ID,I D2 Cohort study/RCT Kaplan—Meier
Cox regression
Risk difference ID, — ID2 RCT Kaplan—Meier
0/E ratio Observed Cohort study/registry study
ID/expected ID in general
population
Quality of life Difference in mean score Xi — Xi Cohort study/RCT Independent t-test
Linear regression
analyses
P,, prevalence group 1; P2, prevalence group 2; CI = cumulative incidence; CI,, CI group 1; C1 2 , CI group 2; ID, incidence density; ID,, ID group 1;
ID 2 , ID group 2; 0/E ratio, observed to expected ratio; RCT, randomized controlled trial; x i , mean score group 1; x i , mean score group 2.
Disease
Confounder
Exposure
(intervention)
PRECISION OF THE ESTIMATE
When interpreting an outcome, we want to know not only the numeri-
cal value of the point estimate, but also the precision with which it has
been estimated. In other words, can we be confident that the observa-
tion is not just a chance finding? The usual standard for accepting an
outcome beyond chance is P (probability) < 0.05. A more informative
description is provided by the 95% confidence interval (CI). The rough
interpretation of the 95% CI is that there is a 95% chance that the real
value lies within the span of the confidence interval.
Statistical significance is strongly dependent on the sample size of
a study. This means that in very large samples an only marginally ele-
vated association can be statistically significant. In contrast, in small
samples, strong associations are sometimes not statistically significant.
The associations, although statistically significant, need not be clini-
cally important. Therefore, the interpretation of findings should not
rely solely on statistical significance.
BIAS
An estimate can be very precise, but still not be accurate because of
bias. Three main sources of bias exist: confounding, selection, and
information bias.
Confounding occurs when the association between exposure and
outcome is influenced by a third variable that is related to both the
exposure and the outcome (Fig. 1.2). A recent study found an associa-
tion between cooking (as occupation) and the incidence of ocular
melanoma.'° It could be argued that as many cooks work at night it
is possible that they could have relatively high exposures to sunlight,
as their leisure activities take place during the day, compared to people
who work during the day. It is implied that the association between
cooking and ocular melanoma could potentially (in part) be explained
by a higher exposure of cooks to sunlight.
Selection bias may occur when the chance of being included in
the study population is not random for all members of the source
r = correlation
Fig. 1.2 Schematic representation of confounding.
population. For example, patients with an advanced tumor stage are
more likely to be referred to a special cancer center than are patients
with a less advanced stage. This is called referral bias. Selection bias
could also be introduced in a study by choosing the wrong control
group, especially if controls are selected from hospital patients.
Information bias occurs when outcome or exposure variables are
not accurately assessed. This is especially problematic when this occurs
differently for exposed versus non-exposed cases, or for cases versus
controls. A well known type of information bias is recall bias. This
refers to the phenomenon that patients tend to remember more details
about exposures that are possibly related to their disease than do con-
trols. For example, patients with uveal melanoma are probably more
aware of the fact that their disease could be related to sunlight expo-
sure. This can lead to an underestimation of exposure in controls and
hence an overestimation of the association with sunlight exposure.
STUDY DESIGNS
There are several research designs, such as case series, cross-sectional,
cohort, randomized control trial, and case—control study, that can be
adopted to address the research question. Each design has its advan-
tages and disadvantages (Table 1.3).
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Table 1.3
	
Advantages and disadvantages of study designs
Considerations	 Type of study
Methodological	 Cross-sectional	 Cohort	 RCT	 Case-control
Confounding	 -	 +	 -
Selection bias	 -	 +/-	 +/-	 -
Information bias	 +/-	 +/-	 +/-	 -
Prior exposure	 -	 +	 +	 -
Incident cases	 -	 +	 +	 +
Practical	 Length of study	 +	 -	 4-/-	 +
Organization	 +	 +/-	 -	 +/-
Expenses	 +	 -	 -	 +
Negative score (--) indicates disadvantage compared to other study designs.
Positive score (+) indicates advantage compared to other study designs.
Equivocal score (+7-) indicates neither advantage nor disadvantage compared to other study
designs.
RCT, randomized controlled trial.
Case series In a case series the authors present the clinical data
regarding a group of patients, e.g. the response of tumors to chemo-
therapy combined with diode laser in retinoblastoma patients. The
disadvantage is that this kind of study is not randomized and does
not have a comparative design, and does not permit an answer
to a question such as 'there is a good response, but compared to
what?"
Cross-sectional study In a cross-sectional study the outcome
(and exposure) are assessed at one point in time. In addition, outcome
between exposed and unexposed study participants can be compared
in order to explore etiological questions. In a cross-sectional study on
the association between iris color and posterior uveal melanoma,
melanoma patients (n = 65) with a light iris color were significantly
more likely to have darker choroidal pigmentation than controls (n =
218) (P = 0.005). In addition, darker choroidal pigmentation was
associated histologically with an increased density of choroidal mela-
nocytes (P = 0.005). The authors concluded that increased choroidal
pigmentation, as a result of an increase in the density of pigmented
choroidal melanocytes, is not protective but may actually be a risk
factor for the development of posterior uveal melanoma in white
patients.12
The cross-sectional study design has the advantage that it is rela-
tively easy to plan, only one measurement is needed, and it is inex-
pensive and quick to perform. As both exposure and outcome are
measured at the same time, we cannot be sure that the exposure pre-
ceded the outcome (the most important criterion for causality). More-
over, the associations found in a cross-sectional study might not be
applicable to incident cases.
Cohort study Some of the problems listed above can be overcome
by conducting a cohort study. At baseline, one starts with a cohort of
people free from disease and the exposure(s) of interest being assessed
at baseline. During or at the end of follow-up, incident cases in both
the unexposed and the exposed group are identified and RRs or HRs
can be calculated. Despite the theoretical advantages of a cohort design,
there are some practical disadvantages. The cohort studies are often
expensive because they need large sample sizes and/or long follow-
4 up to accumulate enough incident cases for meaningful analysis.
Moreover, the potential bias of (residual) confounding can never be
totally excluded.
Randomized controlled trial is a specific type of cohort study.
At the start of the study, participants are randomly assigned to the
intervention group (treatment under investigation) or a control group
(no treatment, placebo, or standard treatment). After the start of a
treatment patients often get better. This may be due to the treatment
or to other circumstances, such as spontaneous resolution, effective
co-interventions, and placebo effects. The best comparison is often
between the new treatment and the best available one, not the sham
treatment." The randomization, if successful, ensures that confound-
ing factors are evenly distributed between the intervention and control
groups.
For clinicians interested in evidence pertaining most directly to a
particular class of patient, subgroup analysis can be very informative.
The strength of evidence for subgroup effects depends on whether
hypotheses have been defined prior to analysis, whether potential
problems regarding multiple comparisons have been considered, and
whether the effects found are biologically plausible. Using these
guidelines, the reader of a trial report should be able to decide whether
the presented subgroup effects are of clinical importance or if the
overall result is a better estimate of treatment effect.14
Case-control study In contrast to cohort studies, the starting
point in case-control is to assess not the exposure status, but the
disease status. People with the disease of interest are selected and a
control group of people without the disease is subsequently recruited.
The control group should include people from the same source popu-
lation as the cases, implying that if any of the controls had developed
the disease, they would have been eligible for inclusion in the study
as a case.
The selection of a valid control group is important in case-control
studies. It is possible to select population controls, hospital controls,
friends or relatives of patients, or any variant of these. 15 Case-control
studies have the advantage of being relatively quick and inexpensive
to conduct, and are especially appealing in rare diseases. A disadvan-
tage is the large potential for selection bias, especially in the recruit-
ment of controls. In addition there is also a real danger of information
(recall) bias.
FURTHER READING
Pilot study A pilot study is often performed before the start of a
large study. Its aim is to improve the methodological quality and
evaluate the feasibility of the study. The results of a pilot study are
often used to gain an impression of the efficacy of an intervention,
which should then be tested in a larger study. The inclusion of pilot
study results in a later cumulative meta-analysis may lead to sufficient
power to assess the efficacy of an experimental intervention.'
Systematic review In a systematic review all the available evi-
dence (literature) on a certain topic is reviewed in a systematic,
transparent, and reproducible manner. These studies can be especially
useful when results from single studies are contradictory and/or have
large confidence intervals because of small sample sizes. When the
studies in a systematic review are reasonably homogeneous, their
results can be pooled in a meta-analysis. This results in one effect size
for all the studies together, with a much smaller confidence interval
than for the individual studies. An example is a systematic review on
the survival of patients with uveal melanoma treated with brachy-
therapy. The result of this meta-analysis showed that the 5-year mela-
noma-related mortality rate was 6% for small and medium tumors,
and 26% for large tumors.'
CONCLUSIONS
In general, ophthalmic tumors are rare compared to other ophthalmic
diseases. Therefore, it is difficult to conduct large studies with enough
power to obtain statistically significant and clinically relevant results.
Several studies are published each year, most of them descriptive and
concerning retrospective patient series. To conduct a randomized clini-
cal trial international collaboration is necessary, so as to include enough
patients in the different treatment arms of the study. Furthermore,
uniform definitions and study methodologies are very important so
that the different studies in the literature can be compared and
systematic reviews and meta-analyses performed.
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